Close Menu

Oxford Nanopore

Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments — MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.

Oxford Nanopore Facts

 

CEO: Gordon Sanghera

Website: www.nanoporetech.com

Ticker symbol: Privately held

Headquarters: Oxford, UK

Number of employees: 250+

NEW YORK (GenomeWeb News) — Oxford Nanopore Technologies has raised £35 million ($59 million) from existing and new investors, bringing its total funding since its founding in 2005 to £180 million ($302 million).

NEW YORK (GenomeWeb) – In a study published on the p

NEW YORK (GenomeWeb) − Researchers from the University of Birmingham in the UK last week publicly released data they generated with Oxford Nanopore Technologies' MinIon nanopore sequencer, the first group to do so since the company started its early access program this spring.

This article, originally published March 18, has been updated with information from Oxford Nanopore Technologies that clarifies the beginning of MinIon shipments.

This article was originally published February 14 and has been modified to include additional comments.

This article has been updated with additional information about the AGBT conference.

A team led by Oxford Nanopore co-founder Hagan Bayley has demonstrated the ability of a nanopore sensor to distinguish between differentially phosphorylated forms of the protein thioredoxin.

This article was originally published Dec. 30.

Oxford Nanopore Technologies opened registration for early access to the MinIon nanopore sequencer last week and provided additional details about the program.

This article has been updated to include Illumina's recorded gain on the sale.
NEW YORK (GenomeWeb News) – Oxford Nanopore Technologies today said that it has coordinated the acquisition of Illumina's 13.5 percent stake in the company on behalf of certain shareholders.

Pages

The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

Washington Post columnist writes that she is skeptical about DNA-based diets.

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.